ClinicalTrials.gg
Not yet recruitingNCT07832630Updated Nov 2, 2026

Saruparib in HRDsig+ Solid Tumors

A Phase 2 interventional study of Saruparib and FoundationOne®CDx in Malignant Neoplastic Disease (Disorder), sponsored by Abramson Cancer Center at Penn Medicine. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Abramson Cancer Center at Penn Medicine · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The main purpose of this study is to study the effect of saruparib, an experimental PARP inhibitor, on tumors that have an Homologous Recombination Deficiency Signature (HRDsig) positive tumor by the investigational FoundationOne®CDx clinical trial assay.

Read the detailed description

This is an open-label, phase II study of saruparib in patients with locally advanced or metastatic solid tumors that are HRDsig+ by FoundationOneCDx (Foundation Medicine, Inc). Patients in Cohort A must also have a pathogenic germline or somatic variant in BRCA1, BRCA2, PALB2, RAD51B, RAD51C, RAD51D or BARD1. The primary endpoint is overall response rate in Cohort A.

02

Conditions studied

  • Malignant Neoplastic Disease (Disorder)

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 124 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Abramson Cancer Center at Penn Medicine is the lead sponsor of 461 studies on the registry; 87 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 14 (42%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eastern Cooperative Oncology () performance status of 0 to 1
  • Diagnosis of a or locally advanced solid tumor for which no cure is considered possible.

    1. Patients with breast, ovarian, prostate or pancreatic cancer may not enroll within Cohort A
    2. Patients with ovarian cancer may not enroll in Cohort B
  • No history of resistance to platinum therapy, defined as disease progression within six months of exposure to platinum chemotherapy (ie cisplatin, oxaliplatin, carboplatin). Patients may be platinum-naïve at time of enrollment.
  • Progressing at time of enrollment
  • Tumor is HRDsig+ by Foundation Medicine Inc assay

    a. Patients in Cohort A must also have a documented pathogenic germline or somatic variant in BRCA1, BRCA2, PALB2, RAD51B, RAD51C, RAD51D or BARD1 as assessed by a CLIA certified laboratory (this can be done at any time prior to enrollment via tissue assay). Central review of variants must be performed by PI prior to patient enrollment.

  • Adequate organ function confirmed by the following laboratory values obtained during the screening period:

    1. (ANC) ≥ 1.5 x 109/L
    2. ≥ 100 x 109/L
    3. ≥ 10g/dL
    4. and AST ≤2.5×; for participants with hepatic metastases, ALT and AST ≤5×ULN
    5. Total ≤ 1.5x ULN. If liver metastases or metabolic disorder such as Gilbert's Syndrome, then ≤2.5x ULN
    6. of ≥ 45 mL/min/1.73m2 as determined by CKD-EPI formula (Inker et al 2021).

      • For male participants with SCr ≤ 0.9 mg/dL, use the following formula:

        142 x (SCr/0.9)-0.302 x 0.9938Age (years)

      • For male participants with SCr > 0.9 mg/dL, use the following formula:

        142 x (SCr/0.9)-1.200 x 0. 9938Age (years)

      • For female participants with SCr \< 0.7 mg/dL, use the following formula:

        142 x (SCr/0.7)-0.241 x 0.9938Age (years) x 1.012

      • For female participants with SCr > 0.7 mg/dL, use the following formula:

        142 x (SCr/0.7)-1.200 x 0.9938Age (years) x 1.012

Exclusion criteria

Exclusion Criteria:

  • Reversion variant in the peripheral blood as assessed by a CLIA certified local assay (Cohort A only)
  • Prior exposure to PARP inhibition
  • Evidence of platinum-resistance, defined as disease progression within six months of exposure to a platinum chemotherapy (ie cisplatin, oxaliplatin, carboplatin)
  • Clinical evidence of uncontrolled malabsorption and/or any other gastrointestinal disorder or defect that would in the opinion of the investigator, interfere with absorption of saruparib
  • Acute infection requiring intravenous antibiotics, antiviral or antifungal agents during the 7 days prior to first dose of saruparib
  • Participants with >2 or higher
  • Evidence of active and uncontrolled and/or . Screening for hepatitis B and hepatitis C is not required. Participants previously exposed to hepatitis B or hepatitis C are eligible if they meet one of the following criteria:

    a. Are negative for HBsAg and anti-HBc; or b. Are HBsAg+ and anti-HBc+ (chronic hepatitis B), and meet conditions i to iii below: i. HBV DNA viral load \< 2000 IU/mL. ii. Have normal aminotransferase values. iii. Start antiviral treatment at least 2 weeks prior to the first dose of study intervention and maintain antiviral treatment during the interventional period.

    c. Are anti-HBc positive, HBsAg negative, and have HBV DNA \< 2000 IU/mL. d. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.

  • Evidence of active and uncontrolled infection. Participants with controlled HIV need to meet the following criteria: undetectable viral RNA load less than 400 copies/mL in the last 4 weeks prior to first dose of study intervention, of ≥ 350 cells/μL, no history of AIDS-defining opportunistic infection within the past 12 months, and stable on the same anti-HIV medications. Screening for HIV is not required.
  • Symptomatic or untreated . The patient can receive a stable dose of before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days. Corticosteroid dose should not exceed 10mg/day of prednisone or its equivalent
  • Expected of \<12 weeks as determined by the investigator
  • For fertile patient (female patient able to become pregnant or male able to father a child), refusal to use effective during the period of the trial
  • Received any systemic treatment for their advanced 3 weeks prior to first dose of saruparib
  • Active drug or alcohol use or dependence that would interfere with study adherence
  • Presence of any other condition that may increase the risk associated with study participation or may interfere with interpretation of study results, and, in the opinion of the investigator, would make the patient inappropriate for entry into the study.
  • Participant meets one or more of the following:

    • Mean resting interval >470 ms, obtained from triplicate ECGs performed at screening.
    • History of QT prolongation associated with other medications that required discontinuation of that medication.
    • Congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.
    • History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment ( Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication or arrhythmias controlled by pacemakers may be permitted based on the Investigator judgement with cardiologist consultation recommended.
  • Concomitant use of known strong inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir). The required prior to starting study treatment is 2 weeks.
  • Concomitant use of known strong CYP3A4 inducers (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort ). The required washout period prior to starting study treatment is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
  • Other malignancy unless curatively treated with no evidence of disease for ≥2 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma. Patients with a history of localized triple negative breast cancer may be eligible, provided they completed their chemotherapy more than three years prior to registration, and that the patient remains free of recurrent or disease
  • Persistent toxicities (>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia and grade 2 prior platinum-therapy-related neuropathy.
  • Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML.
  • History of persisting (> 2 weeks) severe pancytopenia due to any cause (eg, ANC \< 0.5 x 109 /L or \< 50 x 109 /L)
  • As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases including but not limited to uncontrolled hypertension, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, renal transplant, active bleeding diseases, superior vena cava syndrome, extensive interstitial bilateral lung disease which, in the investigator's opinion, makes it undesirable for the subject to participate in the study or that would jeopardise compliance with the protocol.
  • Major surgery (excluding local surgery of isolated lesions for palliative treatment or diagnostic staging) within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery or an anticipated need for major surgery during the study.
  • Participation in another clinical study with exposure to an product within 30 days or five half-lives (whichever is the longer) prior to initiating study treatment
  • Patients with a known to saruparib or any of the of the product.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    Saruparib (AZD5305)

    Saruparib

    Drug: Saruparib · Diagnostic Test: FoundationOne®CDx

Interventions

  • Saruparib (AZD5305) 60mg PO daily

  • Diagnostic testFoundationOne®CDx

    Tumors will be tested for positive HRDsig tumor by the investigational FoundationOne®CDx clinical trial assay.

06

What researchers measure

Primary outcomes

  1. Best objective response as determined by RECIST v.1.1

    Best objective response as assessed by the Investigator per RECIST 1.1

    Time frame: From baseline through documented disease progression (RECIST v1.1) or death from any cause, whichever occurs first, up to 2 years.

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS, as assessed by the Investigator per RECIST 1.1

    Time frame: From first dose of saruparib until documented disease progression (RECIST v1.1) or death from any cause, whichever occurs first, up to 2 years.

  2. Overall survival

    Overall survival, as assessed by the Investigator per RECIST 1.1

    Time frame: From first dose of saruparib until death from any cause, up to 2 years.

  3. Duration of response (DOR)

    DOR as assessed by the Investigator

    Time frame: From first documented complete or partial response until disease progression or death, up to 2 years.

  4. Disease control rate (DCR)

    DCR is defined as the proportion of patients who achieve CR, PR, or SD by RECIST v1.1.

    Time frame: Percentage of participants achieving complete response, partial response, or stable disease per RECIST v1.1, assessed up to 2 years.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in publication.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Starting 6 months after publication

Access criteria: Available via following review and approval by Principle Investigator for additional analyses.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2029, 36 months later.

Of 335 non-industry phase 2 interventional studies under Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 99. This study's planned 36 months is below that.

Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Sep 22, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Nov 1, 2029
CompletionEst.
Nov 1, 2030
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07832630
Collaborators
AstraZeneca, Basser Center for BRCA
Responsible party
Sponsor
First posted
Sep 22, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Nov 1, 2029 (estimated)
Completion
Nov 1, 2030 (estimated)
Last update
Nov 2, 2026

Study contacts

Kim Reiss Binder, MD
Contact
Kim.ReissBinder@pennmedicine.upenn.edu
215-360-0735
Alex Torres
Contact
Alexandra.Torres@Pennmedicine.upenn.edu
267-496-7621
Kim Reiss Binder, MD
principal investigator · Abramson Cancer Center at Penn Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD5305

Start the discussion